Poorly differentiated thyroid carcinoma: molecular, clinico-pathological hallmarks and therapeutic perspectives

CIRELLO, Valentina; GAMBALE, Carla; NIKITSKI, Alyaksandr V.; MASAKI, Chie; ROQUE, João; COLOMBO, Carla

doi:10.23736/s0031-0808.23.05040-1

Cited by 1 publication

(1 citation statement)

References 127 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prognosis of PDTC and ATC is worse than that of DTC [ 14 ]. PDTC and ATC have also lower overall survival (OS) rates, with mean survival of ~3.2 years and 6 months, respectively [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

Antineoplastic Effect of ALK Inhibitor Crizotinib in Primary Human Anaplastic Thyroid Cancer Cells with STRN–ALK Fusion In Vitro

Ferrari,

Ragusa,

Elia

et al. 2024

IJMS

View full text Add to dashboard Cite

Anaplastic thyroid cancer (ATC) is one of the deadliest human cancers and represents <2% of thyroid carcinomas. A therapeutic target for ATC is represented by anaplastic lymphoma kinase (ALK) rearrangements, involved in tumor growth. Crizotinib is an oral small-molecule tyrosine kinase inhibitor of the ALK, MET, and ROS1 kinases, approved in ALK-positive non-small cell lung cancer. Until now, the effect of crizotinib in “primary human ATC cells” (pATCs) with transforming striatin (STRN)–ALK fusion has not been reported in the literature. In this study, we aimed to obtain pATCs with STRN–ALK in vitro and evaluate the in vitro antineoplastic action of crizotinib. Thyroid surgical samples were obtained from 12 ATC patients and 6 controls (who had undergone parathyroidectomy). A total of 10/12 pATC cultures were obtained, 2 of which with transforming STRN–ALK fusion (17%). Crizotinib inhibited proliferation, migration, and invasion and increased apoptosis in 3/10 pATC cultures (2 of which with/1 without STRN–ALK), particularly in those with STRN–ALK. Moreover, crizotinib significantly inhibited the proliferation of AF cells (a continuous cell line obtained from primary ATC cells). In conclusion, the antineoplastic activity of crizotinib has been shown in human pATCs (with STRN–ALK) in preclinical studies in vitro, opening the way to future clinical evaluation in these patients.

show abstract

Section: Introductionmentioning

confidence: 99%